	US 11,850,263 B2
	Nanoparticles conjugated with vasoactive intestinal peptide antagonists
Edmund Waller, Atlanta, GA (US); Susan Thomas, Atlanta, GA (US); Rebecca Pankove, Atlanta, GA (US); Sruthi Ravindranathan, Decatur, GA (US); and David Francis, Atlanta, GA (US)
Assigned to Emory University, Atlanta, GA (US)
Appl. No. 16/763,197
Filed by Emory University, Atlanta, GA (US); and Georgia Tech Research Corporation, Atlanta, GA (US)
PCT Filed Nov. 9, 2018, PCT No. PCT/US2018/060155 § 371(c)(1), (2) Date May 11, 2020, PCT Pub. No. WO2019/094817, PCT Pub. Date May 16, 2019.
Claims priority of provisional application 62/584,196, filed on Nov. 10, 2017.
Prior Publication US 2020/0297767 A1, Sep. 24, 2020
Int. Cl. C07K 14/575 (2006.01); A61K 38/00 (2006.01); A61K 35/17 (2015.01); A61K 47/62 (2017.01); A61K 47/69 (2017.01); A61K 9/00 (2006.01)

CPC A61K 35/17 (2013.01) [A61K 47/62 (2017.08); A61K 47/6935 (2017.08); C07K 14/57563 (2013.01); A61K 9/0019 (2013.01); A61K 38/00 (2013.01)]

10 Claims

1. A method of augmenting T-cell activation and ex vivo expansion by co-incubation of human T cells with a nanoparticle containing a small molecule antagonist of VIP signaling, wherein the antagonist of VIP signaling comprises the VIPhyb peptide sequence as set forth in SEQ ID NO: 1.